How much revenue does Strides Pharma Science make?

Strides Pharma Science reported 43.92 billion INR in revenue for fiscal year 2025, up 12.9% from 38.91 billion INR in fiscal year 2024. In Q3 2026 revenue was 11.95 billion INR.

Where does Strides Pharma Science make most of its revenue?

North America: 56% of revenue by region in fiscal year 2025, followed by Europe (23%).

What companies are similar to Strides Pharma Science?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Alembic Pharmaceuticals Limited (APLLTD.BO), Jubilant Pharmova Limited (JUBLPHARMA.NS), Natco Pharma Limited (NATCOPHARM.NS), Sanofi Cons Healthc IND L (SANOFICONR.BO).

Strides Pharma Science Limited (STAR.NS) Stock

About Strides Pharma Science Limited

Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, an...

At a glance

Strides Pharma Science reported revenue of 43.92 billion INR for fiscal year 2025, up 12.9% from fiscal year 2024, and net income of 35.93 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 11.95 billion INR, up 3.6% from a year before. North America was its largest region in fiscal year 2025, with 56% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.